IFNB1 and myeloid sarcoma: Conversely, a longitudinal analysis of MS patients cohort revealed a significant reduction in migraine frequency for the subgroup of patients who were switched from IFN-β to natalizumab, irrespective of their level of fatigue, anxiety, depression, alexithymia or other clinical variables as well as Migraine Disability Assessment questionnaire scores [95, 96].